Julie A. Kish, MD, FACP

Dr. Julie Kish is a senior member of the Genitourinary Oncology, Head & Neck, and Senior Adult Oncology Programs at Moffitt. She also is a professor at the University of South Florida (USF) College of Medicine.  Her research interests include clinical trials for head, neck and genitourinary cancers. Dr. Kish received her bachelor’s, master’s degree and medical degree from Wayne State University in Detroit, Michigan.  She completed a residency in internal medicine and a fellowship in oncology at Wayne State University Affiliated Hospitals. After completing her training, Dr. Kish was on the faculty at Wayne State School of Medicine and Case Western Reserve University in Cleveland, OH, as well as a physician with Henry Ford Health System in MI.  From 2000-2005, she was a member of the Moffitt team, serving as a principal investigator for both the Southwest Oncology Group (SWOG) and Eastern Cooperative Oncology Group (EOG) and a USF faculty member. In 2006, Dr. Kish left Moffitt to join the San Antonio Cancer Institute in Texas, where she continued as a SWOG principal investigator, and served as a clinical professor at University of Texas Health Science Center.  She returned to Moffitt in 2008. Dr. Kish is a member of the International Society of Geriatric Oncology and is listed in Best Doctors in America®.  

Provider

Julie A. Kish, MD, FACP

Medical Oncology

Call 1-888-Moffitt
(1-888-663-3488)
For an Appointment

Schedule Appointment

Program
Individualized Cancer Management

Print Print Physician Bio

Education & Training

BOARD CERTIFICATION:
  • Medical Oncology
FELLOWSHIP:
  • Wayne State University School of Medicine -
RESIDENCY:
  • Wayne State University School of Medicine -
MEDICAL SCHOOL:
  • Wayne State University - MD
Provider

Julie A. Kish, MD, FACP

Medical Oncology

Call 1-888-Moffitt
(1-888-663-3488)
For an Appointment

Schedule Appointment

Program
Individualized Cancer Management

Print Print Physician Bio

Publications

  • Maggiore R, Zumsteg ZS, BrintzenhofeSzoc K, Trevino KM, Gajra A, Korc-Grodzicki B, Epstein JB, Bond SM, Parker I, Kish JA, Murphy BA, VanderWalde NA. The Older Adult With Locoregionally Advanced Head and Neck Squamous Cell Carcinoma: Knowledge Gaps and Future Direction in Assessment and Treatment. Int J Radiat Oncol Biol Phys. 2017 Jul;98(4):868-883. Pubmedid: 28602414.
  • Strom TJ, Naghavi AO, Trotti AM, Russell J, Kish JA, McCaffrey J, Otto KJ, Harrison LB, Caudell JJ. Increased acute mortality with chemoradiotherapy for locally advanced head and neck cancer in patients ≥70years. Geriatr Oncol. 2017 Jan;8(1):50-55. Pubmedid: 27720129.
  • Naghavi AO, Strom T, Abuodeh YA, Echevarria M, Russell J, Kish JA, Balducci L, Trotti A, Harrison LB, Caudell JJ. Concurrent Chemotherapy in Elderly Patients With Head and Neck Cancer. Int J Radiat Oncol Biol Phys. 2016 Oct;96(2S):E362. Pubmedid: 27674484.
  • Mifsud MJ, Tanvetyanon T, Mccaffrey JC, Otto KJ, Padhya TA, Kish J, Trotti AM, Harrison LB, Caudell JJ. Adjuvant radiotherapy versus concurrent chemoradiotherapy for the management of high-risk salivary gland carcinomas. Head Neck. 2016 Nov;38(11):1628-1633. Pubmedid: 27098984.
  • Frakes JM, Naghavi AO, Demetriou SK, Strom TJ, Russell JS, Kish JA, McCaffrey JC, Otto KJ, Padhya TA, Harrison LB, Trotti AM, Caudell JJ. Determining optimal follow-up in the management of human papillomavirus-positive oropharyngeal cancer. Cancer. 2016 Feb;122(4):634-641. Pubmedid: 26565997.
  • Tanvetyanon T, Padhya T, McCaffrey J, Kish JA, Deconti RC, Trotti A, Rao NG. Postoperative concurrent chemotherapy and radiotherapy for high-risk cutaneous squamous cell carcinoma of the head and neck. Head Neck. 2015 Jun;37(6):840-845. Pubmedid: 24623654.
  • Strom TJ, Trotti AM, Kish J, Russell JS, Rao NG, McCaffrey J, Padhya TA, Otto KJ, Caudell JJ. Comparison of every 3 week cisplatin or weekly cetuximab with concurrent radiotherapy for locally advanced head and neck cancer. Oral Oncol. 2015 Jul;51(7):704-708. Pubmedid: 25936651.
  • Rao NG, Han G, Greene JN, Tanvetyanon T, Kish JA, De Conti RC, Chuong MD, Shridhar R, Biagioli MC, Caudell JJ, Trotti AM. Effect of prophylactic fluconazole on oral mucositis and candidiasis during radiation therapy for head-and-neck cancer. Pract Radiat Oncol. 2014 Mar;3(3):229-233. Pubmedid: 24674369.
  • Gray J, Haura EB, Chiappori A, Tanvetyanon T, Williams CC, Pinder-Schenk M, Kish JA, Kreahling JM, Lush RM, Neuger AM, Tetteh LF, Akar A, Zhao X, Schell MJ, Bepler G, Altiok S. A phase I, pharmacokinetic, and pharmacodynamic study of panobinostat, an HDAC inhibitor, combined with erlotinib in patients with advanced aerodigestive tract tumors. Clin Cancer Res. 2014 Mar;20(6):1644-1655. Pubmedid: 24429877. Pmcid: PMC4051132.
  • Strom T, Trotti AM, Kish J, Rao NG, McCaffrey J, Padhya TA, Lin HY, Fulp W, Caudell JJ. Risk factors for percutaneous endoscopic gastrostomy tube placement during chemoradiotherapy for oropharyngeal cancer. JAMA Otolaryngol Head Neck Surg. 2013 Nov;139(11):1242-1246. Pubmedid: 24136493.
  • May JT, Rao N, Sabater RD, Boutrid H, Caudell JJ, Merchant F, Han G, Padhya TA, McCaffrey JC, Tanvetyanon T, Deconti R, Kish J, McCaffrey TV, Trotti A. Intensity-modulated radiation therapy as primary treatment for oropharyngeal squamous cell carcinoma. Head Neck. 2013 Dec;35(12):1796-1800. Pubmedid: 23468387.
  • Cooper JS, Zhang Q, Pajak TF, Forastiere AA, Jacobs J, Saxman SB, Kish JA, Kim HE, Cmelak AJ, Rotman M, Lustig R, Ensley JF, Thorstad W, Schultz CJ, Yom SS, Ang KK. Long-term follow-up of the RTOG 9501/intergroup phase III trial: postoperative concurrent radiation therapy and chemotherapy in high-risk squamous cell carcinoma of the head and neck. Int J Radiat Oncol Biol Phys. 2012 Dec;84(5):1198-1205. Pubmedid: 22749632. Pmcid: PMC3465463.
  • Swinnen LJ, Rankin C, Carraway H, Albain KS, Townsend JJ, Budd GT, Kish JA, Rivkin SE, Blumenthal DT. A phase II study of cisplatin preceded by a 12-h continuous infusion of concurrent hydroxyurea and cytosine arabinoside (Ara-C) for adult patients with malignant gliomas (Southwest Oncology Group S9149). J Neurooncol. 2008 Feb;86(3):353-358. Pubmedid: 18175205. Pmcid: PMC4051205.
  • Cooper J, Pajak T, Forastiere A, Jacobs J, Saxman S, Kish J, Kim H, Cmelak A, Rotman M, Machtay M, Ensley J, Chao K, Schultz J, Lee N, Fu K. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med. 2004 May;350(19):1937-1944. Pubmedid: 15128893.
  • Adelstein DJ, Li Y, Adams GL, Wagner H, Kish JA, Ensley JF, Schuller DE, Forastiere AA. An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol. 2003 Jan;21(1):92-98. Pubmedid: 12506176.
  • Kish J. Neoadjuvant androgen ablation in localized carcinoma of the prostate. Cancer Control. 2001;8(2):155-162. Pubmedid: 11326170.
  • Kish J, Wolf M, Schellhammer P, Hussain M, Einstein A, Crawford E. Continuous-infusion 5-fluorouracil and cisplatin for advanced/recurrent transitional cell cancer of the bladder: a Southwest Oncology Group trial. Am J Clin Oncol. 1997 Aug;20(4):327-330. Pubmedid: 9256883 .
  • Elias L, Blumenstein B, Kish J, Flanigan R, Wade J, Lowe B, Goodwin J, Crawford E. A phase II trial of interferon-alpha and 5-fluorouracil in patients with advanced renal cell carcinoma: a Southwest Oncology Group study. Cancer. 1996 Sep;78(5):1085-1088. Pubmedid: 8780547 .
  • DiBenedetto J J, Cubeddu L, Ryan T, Kish J, Sciortino D, Beall C, Eisenberg P, Henderson C, Griffin D, Wentz A. Ondansetron for nausea and vomiting associated with moderately emetogenic cancer chemotherapy. Clin Ther. 1995 Nov;17(6):1091-1098. Pubmedid: 8750400 .
  • DiBenedetto J, Cubeddu LX, Ryan T, Kish JA, Sciortino D, Beall C, Eisenberg PD, Henderson C, Griffin D, Wentz A. Ondansetron for nausea and vomiting associated with moderately emetogenic cancer chemotherapy. Clin Ther. 1995;17(6):1091-1098. Pubmedid: 8750400.
  • Kish J, Wolf M, Crawford E, Leimert J, Bueschen A, Neefe J, Flanigan R. Evaluation of low dose continuous infusion 5-fluorouracil in patients with advanced and recurrent renal cell carcinom:a Southwest Oncology Group Study. Cancer. 1994 Aug;74(3):916-919. Pubmedid: 8039119 .
  • Kish JA, Wolf M, Crawford ED, Leimert JT, Bueschen A, Neefe JR, Flanigan RC. Evaluation of low dose continuous infusion 5-fluorouracil in patients with advanced and recurrent renal cell carcinoma. A Southwest Oncology Group Study. Cancer. 1994 Aug;74(3):916-919. Pubmedid: 8039119.
  • Beck T, Hesketh P, Madajewicz S, Navari R, Pendergrass K, Lester E, Kish JA, Murphy W, Hainsworth J, Gandara D, et a. Stratified, randomized, double-blind comparison of intravenous ondansetron administered as a multiple-dose regimen versus two single-dose regimens in the prevention of cisplatin-induced nausea and vomiting. J Clin Oncol. 1992 Dec;10(12):1969-1975. Pubmedid: 1453211 .
  • Higano C, Goodman P, Craig J, Kish J, Rivkin S, Wolf M, Crawford E. Phase II evaluation of amonafide in renal cell carcinoma: a Southwest Oncology Group study. Invest New Drugs. 1991 Nov;9(4):361-363. Pubmedid: 1804814 .
  • Higano CS, Goodman P, Craig JB, Kish JA, Rivkin SE, Wolf M, Crawford ED. Phase II evaluation of amonafide in renal cell carcinoma. A Southwest Oncology Group study. Invest New Drugs. 1991 Nov;9(4):361-363. Pubmedid: 1804814.
  • Kish J. Rehabilitation of head and neck cancer patients: Consensus on recommendations from the international conference on rehabilitation of the head and cancer patient. Head Neck. 1991 Jan;13(1):1-14. Review. Pubmedid: 1989924 .
  • Kish JA, Kopecky K, Samson MK, Von Hoff DD, Fletcher WS, Kempf RA, Muggia FM. Evaluation of fludarabine phosphate in malignant melanoma. A Southwest Oncology Group study. Invest New Drugs. 1991 Feb;9(1):105-108. Pubmedid: 1709151.
  • Kish J, Kopecky K, Samson M, Von Hoff D, Fletcher W, Kempf R, Muggia F. Evaluation of fludarabine phosphate in malignant melanoma: a Southwest Oncology Group study. Invest New Drugs. 1991 Feb;9(1):105-108. Pubmedid: 1709151 .
  • Cheruku R, Tapazoglou E, Ensley J, Kish J, Cummings G, al-Sarraf M. The incidence and significance of thromboembolic complications in patients with high-grade gliomas. Cancer. 1991 Dec;68(12):2621-2624. Pubmedid: 1933812 .
  • al-Sarraf M, Kish J, Ensley J. The Wayne State University experience with adjuvant chemotherapy of head and neck cancer. Hematol Oncol Clin North Am. 1991 Aug;5(4):687-700. Pubmedid: 1890060 .
  • Kish JA, Ensley JF, al-Sarraf M. Phase II evaluation of 4'deoxydoxorubicin in advanced renal cell carcinoma. Am J Clin Oncol. 1990 Feb;13(1):17-18. Pubmedid: 2305717.
  • Kish J, Ensley J, al-Sarraf M. Phase II evaluation of 4'deoxydoxorubicin in advanced renal cell carcinoma. Am J Clin Oncol. 1990 Feb;13(1):17-18. Pubmedid: 2305717 .
  • Kuebler JP, Goodman PJ, Brown TD, Crawford ED, Reitz CL, Knight WA, Kish JA. Phase II study of continuous infusion recombinant gamma interferon in renal carcinoma. A Southwest Oncology Group study. Invest New Drugs. 1990 Aug;8(3):307-309. Pubmedid: 2125585.
  • Ensley J, Maciorowski Z, Hassan M, Pietraszkiewicz H, Heilbrun L, Kish J, Tapazoglou E, Jacobs J, al-Sarraf M. Cellular DNA content parameters in untreated and recurrent squamous cell cancers of the head and neck. Cytometry. 1989 May;10(3):334-338. Pubmedid: 2714116 .
  • de Braud F, Heilbrun L, Ahmed K, Sakr W, Ensley J, Kish J, Tapazoglou E, al-Sarraf M. Metastatic squamous cell carcinoma of an unknown primary localized to the neck: advantages of an aggressive treatment. Cancer. 1989 Jul;64(2):510-515. Pubmedid: 2736495 .
  • Ensley J, Kish J, Weaver A, Jacobs J, Hassan M, Cummings G, Al-Sarraf M. The correlation of specific variables of tumor differentiation with response rate and survival in patients with advanced head and neck cancer treated with induction chemotherapy. Cancer. 1989 Apr;63(8):1487-1492. Pubmedid: 2924257 .
  • Ensley J, Patel B, Kloner R, Kish J, Wynne J, al-Sarraf M. The clinical syndrome of 5-fluorouracil cardiotoxicity. Invest New Drugs. 1989 Apr;7(1):101-109. Pubmedid: 2737845 .
  • Kish J, Ensley J, Jacobs J, Binns P, al-Sarraf M. Evaluation of high-dose cisplatin and 5-FU infusion as initial therapy in advanced head and neck cancer. Am J Clin Oncol. 1988 Oct;11(5):553-557. Pubmedid: 3177258 .
  • LoRusso P, Tapazoglou E, Kish J, Ensley J, Cummings G, Kelly J, al-SarrafM. Chemotherapy for paranasal sinus carcinoma: a 10-year experience at Wayne State University. Cancer. 1988 Jul;62(1):1-5. Pubmedid: 2454717 .
  • Ensley J, Kish J, Tapazoglou E, Jacobs J, Weaver A, Atkinson D, Ahmed K, Mathog R, Al-Sarraf M. An intensive, five course, alternating combination chemotherapy induction regimen used in patients with advanced, unresectable head and neck cancer. J Clin Oncol. 1988 Jul;6(7):1147-1153. Pubmedid: 3292714 .
  • Al-Kourainy K, Crissman J, Ensley J, Kish J, Kelly J, Al-Sarraf M. Excellent response to cis-platinum-based chemotherapy in patients with recurrent or previously untreated advanced nasopharyngeal carcinoma. Am J Clin Oncol. 1988 Aug;11(4):427-430. Pubmedid: 2457306 .
  • Tapazoglou E, Kish J, Ensley J, Al-Sarraf M. Response rate and toxicity with aziridinylbenzoquinone in patients with recurrent gliomas. A progress report. Am J Clin Oncol. 1988 Aug;11(4):474-478. Pubmedid: 3407628 .
  • Ensley J, Maciorowski Z, Pietraszkiewicz H, Hassan M, Kish J, Al-Sarraf M, Jacobs J, Weaver A, Atkinson D, Crissman J. Solid tumor preparation for clinical application of flow cytometry. Cytometry. 1987 Sep;8(5):488-493. Pubmedid: 3665673 .
  • Ensley J, Maciorowski Z, Pietraszkiewicz H, Klemic G, KuKuruga M, SaparetoS, Corbett T, Crissman J, Kish J. Solid tumor preparation for flow cytometry using a standard murine model. Cytometry. 1987 Sep;8(5):479-487. Pubmedid: 2444398 .
  • Patel B, Kloner R, Ensley J, Al-Sarraf M, Kish J, Wynne J. 5-Fluorouracil cardiotoxicity: left ventricular dysfunction and effect of coronary vasodilators. Am J Med Sci. 1987 Oct;294(4):238-243. Pubmedid: 3661619 .
  • Jacobs J, Weaver A, Ahmed K, Crissman J, Ensley J, Kish J, Cummings G, al-Sarraf M. Proto-chemotherapy in advanced head and neck cancer. Head Neck Surg. 1987 Nov;10(2):93-98. Pubmedid: 3333768 .
  • Al-Sarraf M, Metch B, Kish J, Ensley J, Rinehart J, Schuller D, Coltman CAJr. Platinum analogs in recurrent and advanced head and neck cancer: a Southwest Oncology Group and Wayne State University Study. Cancer Treat Rep. 1987 Jul;71(7-8):723-726. Pubmedid: 3300967 .
  • Al-Kourainy K, Kish J, Ensley J, Tapazoglou E, Jacobs J, Weaver A, CrissmanJ, Cummings G, Al-Sarraf M. Achievement of superior survival for histologically negative versus histologically positive clinically complete responders to cisplatin combination in patients with locally advanced head and neck cancer. Cancer. 1987 Jan;59(2):233-238. Pubmedid: 2433016 .
  • Jacobs J, Kish J, Ensley J, Ahmad K, Weaver A, Crissman J, Al-Sarraf M. Combined modality therapy utilizing a cisplatin combination for effective chemotherapy in patients with previously untreated head and neck cancer. Am J Surg. 1986 Oct;152(4):451-455. Pubmedid: 2429570 .
  • Kish J, Ensley J, Al-Sarraf M. Phase II evaluation of diaziquone in recurrent head and neck cancer. Cancer Treat Rep. 1986 May;70(5):671-672. Pubmedid: 3708616 .
  • Tapazoglou E, Kish J, Ensley J, Al-Sarraf M. The activity of a single-agent 5-fluorouracil infusion in advanced and recurrent head and neck cancer. Cancer. 1986 Mar;57(6):1105-1109. Pubmedid: 3943034 .
  • Ensley J, Crissman J, Kish J, Jacobs J, Weaver A, Kinzie J, Cummings G, Al-Sarraf M. The impact of conventional morphologic analysis on response rates and survival in patients with advanced head and neck cancers treated initially with cisplatin-containing combination chemotherapy. Cancer. 1986 Feb;57(4):711-717. Pubmedid: 3943009 .
  • Rooney M, Kish J, Jacobs J, Kinzie J, Weaver A, Crissman J, Al-Sarraf M. Improved complete response rate and survival in advanced head and neck cancer after three-course induction therapy with 120-hour 5-FU infusion and cisplatin. Cancer. 1985 Mar;55(5):1123-1128. Pubmedid: 4038469 .
  • Kish J, Ensley J, Jacobs J, Weaver A, Cummings G, Al-Sarraf M. A randomized trial of cisplatin (CACP) + 5-fluorouracil (5-FU) infusion and CACP + 5-FU bolus for recurrent and advanced squamous cell carcinoma of the head and neck. Cancer. 1985 Dec;56(12):2740-2744. Pubmedid: 3902199 .
  • Kish JA, Ensley JF, Jacobs J, Weaver A, Cummings G, Al-Sarraf M. A randomized trial of cisplatin (CACP) + 5-fluorouracil (5-FU) infusion and CACP + 5-FU bolus for recurrent and advanced squamous cell carcinoma of the head and neck. Cancer. 1985 Dec;56(12):2740-2744. Pubmedid: 3902199.
  • Ensley J, Jacobs J, Weaver A, Kinzie J, Crissman J, Kish J, Cummings G, Al-Sarraf M. Correlation between response to cisplatinum-combination chemotherapy and subsequent radiotherapy in previously untreated patients with advanced squamous cell cancers of the head and neck. Cancer. 1984 Sep;54(5):811-814. Pubmedid: 6204738 .
  • Ensley JF, Jacobs JR, Weaver A, Kinzie J, Crissman J, Kish JA, Cummings G, Al-Sarraf M. Correlation between response to cisplatinum-combination chemotherapy and subsequent radiotherapy in previously untreated patients with advanced squamous cell cancers of the head and neck. Cancer. 1984 Sep;54(5):811-814. Pubmedid: 6204738.
  • Kish J, Al-Sarraf M. Aclacinomycin. Phase II evaluation in advanced squamous carcinoma of the head and neck. Am J Clin Oncol. 1984 Oct;7(5):535-537. Pubmedid: 6507374 .
  • Weaver A, Fleming S, Ensley J, Kish J, Jacobs J, Kinzie J, Crissman J, Al-Sarraf M. Superior clinical response and survival rates with initial bolus of cisplatin and 120 hour infusion of 5-fluorouracil before definitive therapy for locally advanced head and neck cancer. Am J Surg. 1984 Oct;148(4):525-529. Pubmedid: 6207742 .
  • Weaver A, Fleming S, Ensley J, Kish JA, Jacobs J, Kinzie J, Crissman J, Al-Sarraf M. Superior clinical response and survival rates with initial bolus of cisplatin and 120 hour infusion of 5-fluorouracil before definitive therapy for locally advanced head and neck cancer. Am J Surg. 1984 Oct;148(4):525-529. Pubmedid: 6207742.
  • Kish JA, Al-Sarraf M. Aclacinomycin. Phase II evaluation in advanced squamous carcinoma of the head and neck. Am J Clin Oncol. 1984 Oct;7(5):535-537. Pubmedid: 6507374.
  • Kish JA, Weaver A, Jacobs J, Cummings G, Al-Sarraf M. Cisplatin and 5-fluorouracil infusion in patients with recurrent and disseminated epidermoid cancer of the head and neck. Cancer. 1984 May;53(9):1819-1824. Pubmedid: 6538456.
  • Haas C, Fabian C, Stephens R, Kish J. Vindesine in head and neck cancer: a Southwest Oncology Group Phase II pilot study. Invest New Drugs. 1983 Oct;1(4):339-340. Pubmedid: 6678881 .
  • Weaver A, Flemming S, Kish J, Vandenberg H, Jacob J, Crissman J, Al-Sarraf M. Cis-platinum and 5-fluorouracil as induction therapy for advanced head and neck cancer. Am J Surg. 1982 Oct;144(4):445-448. Pubmedid: 6889819 .
  • Kish J, Drelichman A, Jacobs J, Hoschner J, Kinzie J, Loh J, Weaver A, Al-Sarraf M. Clinical trial of cisplatin and 5-FU infusion as initial treatment for advanced squamous cell carcinoma of the head and neck. Cancer Treat Rep. 1982 Mar;66(3):471-474. Pubmedid: 7037180 .
  • Crane L, Kish J, Ratanatharathorn V, Merline J, Raval M. Fatal syncytial virus pneumonia in a laminar airflow room. Jama. 1981 Jul;246(4):366-367. Pubmedid: 7241785 .
  • Kish J, Bukkapatnam R, Palazzo F. The treatment challenge of hormone-refractory prostate cancer. Cancer Control. 8(6):487-495. Pubmedid: 11807418.
  • Kish J, Benedetti J, Balcerzak S, Veith R, Davis R, Pollock T, SchullerDE, Ensley J. Feasibility trial of postoperative radiotherapy and cisplatin followed by three courses of 5-FU and cisplatin in patients with resected head and neck cancer: a Southwest Oncology Group study. Cancer J Sci Am. 5(5):307-311. Pubmedid: 10526672.

Provider

Julie A. Kish, MD, FACP

Medical Oncology

Call 1-888-Moffitt
(1-888-663-3488)
For an Appointment

Schedule Appointment

Program
Individualized Cancer Management

Print Print Physician Bio

Participating Trials

CLINICAL TRIAL 17716
A Biomarker-related Approach to Screening for HPV-related Oropharyngeal Cancer
Condition: Head & Neck
Intervention:
Open

CLINICAL TRIAL 17799
A Phase I Dose Escalation Trial of Stereotactic Body Radiotherapy and Concurrent Cisplatin for Re-Irradiation of Unresectable, Recurrent Squamous Cell Carcinomas of the Head and Neck
Condition: Head & Neck
Intervention: cisplatin
Open

CLINICAL TRIAL 17459
A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 with Androgen Deprivation Therapy + Bicalutamide in Patients with Newly Diagnosed Metastatic Sensitive Prostate Cancer
Condition: Genitourinary
Intervention: Bicalutamide; Casodex (Bicalutamide); Lupron (leuprolide acetate); TAK-700 (Orteronel); goserelin acetate (Zoladex); leuprolide acetate
Open

CLINICAL TRIAL 18492
A Single-arm, Phase 2 Study to Evaluate the Safety and Efficacy of VT-464 in Patients with Castration-Resistant Prostate Cancer Progressing on Enzalutamide or Abiraterone
Condition: Genitourinary
Intervention: VT-464
Open

CLINICAL TRIAL 18509
A Phase 3 Randomized, Double-blind, Multi-center Study of Adjuvant Nivolumab versus Placebo in Subjects with High Risk Invasive Urothelial Carcinoma
Condition: Genitourinary
Intervention: BMS-936558 (Nivolumab); Nivolumab; Placebo
Open

CLINICAL TRIAL 17981
A Pilot Study of Adaptive Abiraterone Therapy for Metastatic Castration Resistant Prostate Cancer
Condition: Genitourinary
Intervention: Abiraterone acetate; Zytiga (Abiraterone acetate)
Open

CLINICAL TRIAL 17773
A Phase 1 Study of the Safety and Pharmacokinetics of Escalating Doses of ASG-22CE Given as Monotherapy in Subjects with Metastatic Urothelial Cancer and Other Malignant Solid Tumors that Express Nectin-4
Condition: Genitourinary
Intervention: ASG-22CE
Open

CLINICAL TRIAL 18612
A Randomized Phase II/III Study of Adjuvant Concurrent Radiation and Chemotherapy versus Radiation Alone in Resected High-Risk Malignant Salivary Gland Tumors
Condition: Head & Neck
Intervention: cisplatin
Open

CLINICAL TRIAL 18422
Molecular Analysis for Therapy Choice (MATCH)
Condition: Multiple
Intervention: AZD9291 (Osimertinib); Ado-Trastuzumab emtansine; Afatinib; BIBW 2992 (Afatinib); Crizotinib; Defactinib (VS-6063); GDC-0032 (Taselisib); GSK1120212 (Trametinib); GSK2118436 (dabrafenib); Sunitinib Malate (SU011248); Taselisib; Trametinib; VS-6063; Xalkori (Crizotinib); dabrafenib
Open

CLINICAL TRIAL 18227
Randomized Phase II and Phase III Studies of Individualized Treatment for Nasopharyngeal Carcinoma Based on Biomarker Epstein Barr Virus (EBV) Deoxyribonucleic Acid (DNA)
Condition: Head & Neck
Intervention: 5-fluorouracil; Gemzar (gemcitabine); Not Applicable; Taxol (paclitaxel); cisplatin; gemcitabine; paclitaxel
Open

CLINICAL TRIAL 18683
A Phase 3, Multinational, Randomized, Open-Label, Parallel-Arm Study of Avelumab (MSB0010718C) in Combination with Axitenib (INLYTA®) Versus Sunitinub (SUTENT®) Monotherapy in the First-Line Treatment of Patients with Advanced Renal Cell Carcinoma
Condition: Genitourinary
Intervention: Avelumab; MSB00100718C (Avelumab); Sunitinib Malate (SU011248); axitinib (AG-013736)
Open

CLINICAL TRIAL 18878
A Single-Arm, Multicenter, Phase 2 Trial to Evaluate Efficacy and Safety of Lenvatinib in Combination with Everolimus in Subjects with Unresectable Advanced or Metastatic Non Clear Cell Renal Cell Carcinoma (nccRCC) Who Have Not Received any Chemotherapy for Advanced Disease
Condition: Genitourinary
Intervention: E7080 (Lenvatinib); Lenvatinib (Lenvima); everolimus (RAD001)
Open

CLINICAL TRIAL 18527
Non-Comparative, Open-Label, Multiple Cohort, Phase 1/2 Study of Nivolumab Monotherpay and Nivolumab Combination Therapy in Subjects with Virus-Positive and Virus-Negative Solid Tumors
Condition: Multiple
Intervention: BMS-936558 (Nivolumab); BMS-986016; Daratumumab; Ipilimumab; Nivolumab; Not Applicable; Yervoy (Ipilimumab)
Open

CLINICAL TRIAL 18527
Non-Comparative, Open-Label, Multiple Cohort, Phase 1/2 Study of Nivolumab Monotherpay and Nivolumab Combination Therapy in Subjects with Virus-Positive and Virus-Negative Solid Tumors
Condition: Multiple
Intervention: BMS-936558 (Nivolumab); BMS-986016; Daratumumab; Ipilimumab; Nivolumab; Not Applicable; Yervoy (Ipilimumab)
Open

CLINICAL TRIAL 18902
A Randomized Double-Blind Phase 3 Study of Avelumab in Combination with Standard of Care Chemoradiotherapy (Cisplatin Plus Definitive Radiation Therapy) Versus Standard of Care Chemoradiotherapy in the Front-Line Treatment of Patients with Locally Advanced Squamous Cell Carcinoma of the Head and Neck
Condition: Head & Neck
Intervention: Avelumab; MSB00100718C (Avelumab); Placebo; Radiotherapy; cisplatin
Open

CLINICAL TRIAL 18536
Coordinated High Dose Interleukin-2 (aldesleukin, Proleukin) and Pembrolizumab (anti-PD1, Keytruda) for Therapy of Metastatic Kidney Cancer
Condition: Genitourinary
Intervention: IL-2 (Interleukin-2); Pembrolizumab (Keytruda)
Open

CLINICAL TRIAL 18838
An Open Label, Randomized, Two Arm Phase III Study of Nivolumab in Combination with Ipilimumab versus Extreme Study Regimen (cetuximab + cisplatin/carboplatin + fluorouracil) as First Line Therapy in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Condition: Head & Neck
Intervention: 5-fluorouracil; BMS-936558 (Nivolumab); Cetuximab; Erbitux (Cetuximab); Ipilimumab; Nivolumab; Paraplatin (carboplatin); Yervoy (Ipilimumab); carboplatin; cisplatin
Open

CLINICAL TRIAL 18839
A Double-Blind, Randomized, Two Arm Phase 2 Study of Nivolumab in Combination with Ipilimumab versus Nivolumab in Combination with Ipilimumab Placebo In Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN).
Condition: Head & Neck
Intervention: BMS-936558 (Nivolumab); Ipilimumab; Nivolumab; Placebo; Yervoy (Ipilimumab)
Open

CLINICAL TRIAL 17985
A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCB024360 in Combination With MEDI4736 in Subjects With Selected Advanced Solid Tumors
Condition: Multiple
Intervention: INCB024360 (Epacadostat); MEDI4736 (Durvalumab)
Open

CLINICAL TRIAL 18885
A Randomized, Double-Blind, Placebo-Controlled Phase III Study of ODM-201 Versus Placebo in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Patients with Metastatic Hormone-Sensitive Prostate Cancer
Condition: Genitourinary
Intervention: ODM-201; Placebo; Taxotere (docetaxel); docetaxel
Open

If you believe you are eligible for one of these trials or studies, please call
1-888-MOFFITT (1-888-663-3488).


Provider

Julie A. Kish, MD, FACP

Medical Oncology

Call 1-888-Moffitt
(1-888-663-3488)
For an Appointment

Schedule Appointment

Program
Individualized Cancer Management

Print Print Physician Bio